Adlai Nortye Group
ANL
14.05
-0.41
-2.84%
Adlai Nortye Group
US · ANL
#3309 by market cap
Listed 2023
14.05
-0.41
-2.84%
Live - 5344 symbols - heartbeat 198s ago
· 2026-10-08 08:39
Pre-market
14.05
0.00%
After-hours
14.05
0.00%
- Market cap
- 904.79M
- P/E (TTM)i
- -21.29
- P/Bi
- 4.21
- EPSi
- -1.11
- Div yieldi
- 0.00%
- 52W posi
- 80%
Reader sentiment
Are you bullish or bearish on ANL?
Anonymous reader poll. Unscientific, not investment advice.
About Adlai Nortye Group
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
- Founded
- 2018
- CEO
- Mr. Yang Lu
- Employees
- 109
- Headquarters
- Hangzhou, Zhejiang, China
- Fiscal year end
- 12-31
- Website
- adlainortye.com
Company profile
- Exchange
- US
- Symbol
- ANL
- Market-cap rank
- #3309
- Listing date
- 2023-09-29
- Market cap
- 904.79M
- Float cap
- 696.41M
- Shares out
- 64.40M
- Float shares
- 49.57M
Sectors & themes
Biotechnology
Chinese Concept
Quote time 2026-10-08 08:39:08 · For reference only, not investment advice and not tailored to your situation.